Vivos Inc., founded with the mission to revolutionize cancer treatment, specializes in developing advanced manufacturing equipment for the production of medical isotopes. Their flagship product, RadioGel®, represents a next-generation approach to cancer therapy known as Precision Radionuclide Therapy (PRnT)™. This innovative treatment involves inserting a radionuclide device directly into tumor tissue, offering a targeted and potentially more effective treatment option. Vivos Inc. is currently focused on gaining regulatory approval for human clinical trials.
Notable figures affiliated with Vivos Inc. include experts in medical technology and oncology, although specific names are not provided. The company has achieved significant milestones, including securing patents for their RadioGel® technology and progressing towards an Investigational Device Exemption (IDE) submission. Vivos Inc.'s impact lies in its potential to transform cancer treatment through more precise and localized therapeutic methods, aiming to improve patient outcomes significantly.
